Virpax Pharmaceuticals's market cap is currently $5.98M. The company's EPS TTM is $-8.82; its P/E ratio is ―; Virpax Pharmaceuticals is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Income	$ -15.69M	$ -21.85M	$ -12.03M	$ -4.20M	$ -3.18M
EBITDA	$ -15.19M	$ 0.00	$ 0.00	$ -4.19M	$ 0.00
Net Income	$ -15.19M	$ -21.46M	$ -12.15M	$ -4.49M	$ -3.43M
Balance Sheet
Cash & Short-Term Investments	$ 9.14M	$ 19.00M	$ 36.84M	$ 54.80K	$ 41.54K
Total Assets	$ 9.63M	$ 19.67M	$ 39.57M	$ 465.41K	$ 46.72K
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 1.57M	$ 1.26M
Net Debt	$ -9.14M	$ -19.00M	$ -36.84M	$ 1.51M	$ 1.22M
Total Liabilities	$ 7.69M	$ 3.09M	$ 2.09M	$ 4.68M	$ 2.78M
Stockholders' Equity	$ 1.93M	$ 16.58M	$ 37.48M	$ -4.22M	$ -2.73M
Cash Flow
Free Cash Flow	$ -9.85M	$ -17.85M	$ -14.54M	$ -1.38M	$ -1.13M
Operating Cash Flow	$ -9.85M	$ -17.85M	$ -14.54M	$ -1.38M	$ -1.13M
Investing Cash Flow	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Financing Cash Flow	$ 0.00	$ 0.00	$ 51.33M	$ 1.40M	$ 1.13M

Currency in USD

Virpax Pharmaceuticals Earnings and Revenue History

Income Statement >

Virpax Pharmaceuticals Debt to Assets

Balance Sheet >

Virpax Pharmaceuticals Cash Flow

Cash Flow >

Virpax Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing